Status: Recruiting
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
Participants needed: 39
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Jinling Hospital, ChinaUpdated: Dec 5, 2025Locations: 1Duration: 12 Weeks
Eligibility criteria
Subjects have fully understood and voluntarily signed the informed consent form... [+4]
A history of malignancies other than the disease studied within the past 5 years... [+15]